NCT05027828Recruiting
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 25 Aug 2021
- Start date
- 1 Sept 2021
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Diseases
- Ovarian cancer
- NCT number
- NCT05027828
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Sept 2021 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgical treatment cannot be performed after evaluation;
- Patients who do not agree to use clinical first-line targeted drugs;
Other illness
- Pathologically confirmed as non-epithelial ovarian cancer;
- Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment;
- Severe mental illness;
- Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.
Who the study is looking for
- Ovarian cancer first diagnosed and treated;
- Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer;
- The stage of the disease is II-IV, and surgery will be performed after evaluation;
- Age ≥ 18 years old;
- Subjects and their families fully understand the research plan and sign an informed consent form.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.